To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort.

@article{Granziera2015ToTO,
  title={To treat or not to treat very elderly na{\"i}ve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort.},
  author={Serena Granziera and Giulia Bertozzo and Vittorio Pengo and Lucia Marigo and Gentian Denas and Florinda Petruzzellis and K. Rossi and Tiziana Infante and Seena Jose Padayattil and Egle Perissinotto and Enzo Manzato and Giovanni Nante},
  journal={Internal and emergency medicine},
  year={2015},
  volume={10 7},
  pages={795-804}
}
Despite the recommendations in the guidelines, physicians still underuse warfarin in very elderly patients with non-valvular atrial fibrillation (NVAF). The risks of stroke and major bleeding both increase with age, but it is still not clear whether the beneficial effects of vitamin K antagonists (VKA) in preventing stroke outweigh the related bleeding… CONTINUE READING